References
- Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and Meta-analysis. JAMA Oncol. 2020;6(3):375–384.
- Polite B, Conti RM, Ward JC. Reform of the buy-and-Bill system for outpatient chemotherapy care is inevitable: perspectives from an economist, a realpolitik, and an oncologist. Am Soc Clin Oncol Educ Book. 2015;35:e75–e80.
- US Centers for Medicare and Medicaid Services Medicare Part B Drug Spending Dashboard. 2021. [cited 2021 Jan 21]. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartB
- Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor Drugs. JAMA Netw Open. 2020;3(3):e200423.
- Malin JL, Weeks JC, Potosky AL, et al. Medical oncologists’ perceptions of financial incentives in cancer care. J Clin Oncol. 2013;31(5):530–535.
- Das S, Lo AW. Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program. Contemp Clin Trials. 2017;62:168–174.